Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Hemangiosarcoma 2Sarcoma 1Oligodendroglioma 1Gliosarcoma 1Glioma 1Glioblastoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 45Radiotherapy 20Filgrastim 17Carmustine 15Carboplatin 15Irinotecan 13Bevacizumab 13Magnetic Resonance Spectroscopy 12Surgical Procedures, Operative 11Peripheral Blood Stem Cell Transplantation 9Erlotinib Hydrochloride 9sargramostim 8O(6)-benzylguanine 8Radiation 7Topotecan 6Thiotepa 6Radiotherapy, Intensity-Modulated 6Procarbazine 6Etoposide 6Drug Therapy 6Cyclophosphamide 6Chemotherapy, Adjuvant 6aldesleukin 5Vorinostat 5Sirolimus 5Imatinib Mesylate 5Granulocyte Colony-Stimulating Factor 5Busulfan 52-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 5temsirolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Astrocytoma × carotuximab × Sarcoma × Clear all
NCT01648348 2018-05-23

Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 1/2 Completed
116 enrolled 17 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡